DARK classics in chemical neuroscience: etonitazene and related benzimidazoles

Summary information for this document is not currently available.

Abstract

This abstract is provided here as a convenience only. Check the publisher's website (if available) for the definitive version.

Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which “brorphine” made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.

 

Date 24 March 2021
Location 
Washington, DC
Access
Open access
Publisher 
American Chemical Society
Geographical scope
EU/Europe
Journal 
ACS Chemical Neuroscience
Published online: 24 March 2021 - DOI: 10.1021/acschemneuro.1c00037
Authors 
Ujváry, I; Christie, R; Evans-Brown, M; Gallegos, A; Jorge, R; de Morais, J; Sedefov, R
Publisher's DOI:
10.1021/acschemneuro.1c00037
Document language
English

Main subject

Target audience

Loading